Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPOSE study of subcutaneous pegtibatinase in classical homocystinuria
2023-509074-31-00Phase 2Authorised
- Sponsor
- Travere Therapeutics
- Start
- Jul 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 2, double-blind trial of pegtibatinase in homocystinuria (HCU) (4 arms), sponsored by Travere Therapeutics. Planned start Jul 2026; status: authorised.
02
Drugs
pegtibatinase
03
Conditions
homocystinuria (HCU)
Beyond the preview
Go deeper on 2023-509074-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509074-31-00.